Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 3 12Phase 1/2 5Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Sarcoma 1Gastrointestinal 1

Conditions

Neoplasms 8Melanoma 6Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Nasopharyngeal Carcinoma 2Liver Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Advanced Solid Tumors 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Primary Condition: Advanced Tumors 1Neuroendocrine Tumors 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Locoregionally Advanced Laryngo-hypopharyngeal Squamous Cell Cancer 1Kidney Neoplasms 1High-Risk Resectable NSCLC 1Head and Neck Neoplasms 1Esophageal Neoplasms 1

Interventions

Gemcitabine 6pembrolizumab 5toripalimab 2fludarabine 2Valproic Acid 2Valganciclovir 2Injections 2Cyclophosphamide 2Cisplatin 2130-nm albumin-bound paclitaxel 2tislelizumab 1spartalizumab 1sapropterin 1fosaprepitant 1fludarabine phosphate 1camrelizumab 1Surgical Procedures, Operative 1Specimen Handling 1SHR-1701 1Protons 1Proton Therapy 1Panobinostat 1Medicare Part B 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Floxuridine 1Everolimus 1Dexamethasone 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Nasopharyngeal Carcinoma × toripalimab × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

NCT04073784 2022-04-26

Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Sun Yat-sen University

Phase 1 Unknown
41 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡